7371 related articles for article (PubMed ID: 12941039)
1. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
Amirkhosravi A; Mousa SA; Amaya M; Francis JL
J Thromb Haemost; 2003 Sep; 1(9):1972-6. PubMed ID: 12941039
[TBL] [Abstract][Full Text] [Related]
2. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy.
Mousa SA; Mohamed S
Oncol Rep; 2004 Oct; 12(4):683-8. PubMed ID: 15375485
[TBL] [Abstract][Full Text] [Related]
4. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma.
Amirkhosravi A; Meyer T; Chang JY; Amaya M; Siddiqui F; Desai H; Francis JL
Thromb Haemost; 2002 Jun; 87(6):930-6. PubMed ID: 12083498
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor.
Mousa SA; Mohamed S
Thromb Haemost; 2004 Sep; 92(3):627-33. PubMed ID: 15351861
[TBL] [Abstract][Full Text] [Related]
6. The role of tissue factor pathway inhibitor in tumor growth and metastasis.
Amirkhosravi A; Meyer T; Amaya M; Davila M; Mousa SA; Robson T; Francis JL
Semin Thromb Hemost; 2007 Oct; 33(7):643-52. PubMed ID: 18000790
[TBL] [Abstract][Full Text] [Related]
7. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model.
Sudha T; Phillips P; Kanaan C; Linhardt RJ; Borsig L; Mousa SA
Clin Exp Metastasis; 2012 Jun; 29(5):431-9. PubMed ID: 22415710
[TBL] [Abstract][Full Text] [Related]
9. Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth.
Kragh M; Binderup L; Vig Hjarnaa PJ; Bramm E; Johansen KB; Frimundt Petersen C
Oncol Rep; 2005 Jul; 14(1):99-104. PubMed ID: 15944775
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the pharmacokinetic profiles of two LMWHs--bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)--administered subcutaneously to healthy male volunteers.
Depasse F; González de Suso MJ; Lagoutte I; Fontcuberta J; Borrell M; Samama MM
Thromb Res; 2003 Jan; 109(2-3):109-17. PubMed ID: 12706639
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide.
Mousa SA; Johansen K
Int Angiol; 2005 Mar; 24(1):40-2. PubMed ID: 15876997
[TBL] [Abstract][Full Text] [Related]
12. Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity.
Stevenson JL; Choi SH; Varki A
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7003-11. PubMed ID: 16203794
[TBL] [Abstract][Full Text] [Related]
13. Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis.
Goertz L; Schneider SW; Desch A; Mayer FT; Koett J; Nowak K; Karampinis I; Bohlmann MK; Umansky V; Bauer AT
Oncotarget; 2016 Oct; 7(42):68527-68545. PubMed ID: 27602496
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects.
Mousa SA; Bozarth J; Barrett JS
J Clin Pharmacol; 2003 Jul; 43(7):727-34. PubMed ID: 12856386
[TBL] [Abstract][Full Text] [Related]
15. Extracellular vesicles from malignant effusions induce tumor cell migration: inhibitory effect of LMWH tinzaparin.
Gamperl H; Plattfaut C; Freund A; Quecke T; Theophil F; Gieseler F
Cell Biol Int; 2016 Oct; 40(10):1050-61. PubMed ID: 27435911
[TBL] [Abstract][Full Text] [Related]
16. Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis.
Lee DY; Park K; Kim SK; Park RW; Kwon IC; Kim SY; Byun Y
Clin Cancer Res; 2008 May; 14(9):2841-9. PubMed ID: 18451252
[TBL] [Abstract][Full Text] [Related]
17. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
[TBL] [Abstract][Full Text] [Related]
18. Sulfated non-anticoagulant low molecular weight heparin in the prevention of cancer and non-cancer associated thrombosis without compromising hemostasis.
Darwish NHE; Godugu K; Mousa SA
Thromb Res; 2021 Apr; 200():109-114. PubMed ID: 33582600
[TBL] [Abstract][Full Text] [Related]
19. The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
Sassi M; Chakroun T; Mbemba E; Van Dreden P; Elalamy I; Larsen AK; Gerotziafas GT
Clin Appl Thromb Hemost; 2017 Mar; 23(2):155-163. PubMed ID: 27609342
[TBL] [Abstract][Full Text] [Related]
20. Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin.
Sudha T; Yalcin M; Lin HY; Elmetwally AM; Nazeer T; Arumugam T; Phillips P; Mousa SA
Cancer Lett; 2014 Aug; 350(1-2):25-33. PubMed ID: 24769074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
